Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 29, 2026 is 27.23 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 14.38 % — a change of 89.40% (higher).

FCF Conversion

27.23 %

YoY

89.40%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Shanghai Fudan Forward S&T Co is 2025 27.23 % . FCF Conversion Rate (FCF/EBITDA) of Shanghai Fudan Forward S&T Co was 2024 14.38 % . It decreases by 89.40% higher compared to the previous year.

The Shanghai Fudan Forward S&T Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
258.54 CNY
Jan 1, 2019
9.86 CNY
Jan 1, 2020
-66.11 CNY
Jan 1, 2021
-17.70 CNY
Jan 1, 2022
-116.82 CNY
Jan 1, 2023
2.17 CNY
Jan 1, 2024
14.38 CNY
Jan 1, 2025
27.23 CNY
The Shanghai Fudan Forward S&T Co FCF Conversion history
YEARFCF ConversionYoY
27.23 %+89.40%
14.38 %+562.64%
2.17 %-101.86%
-116.82 %+560.04%
-17.70 %-73.23%
-66.11 %-770.62%
9.86 %-96.19%
258.54 %+52.80%
169.20 %-187.99%
-192.30 %+435.20%
-35.93 %-84.47%
-231.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

FCF Conversion Rate (FCF/EBITDA) of Shanghai Fudan Forward S&T Co is 27.23 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Shanghai Fudan Forward S&T Co changed from 14.38 % to 27.23 %, representing a 89.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Shanghai Fudan Forward S&T Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Shanghai Fudan Forward S&T Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Shanghai Fudan Forward S&T Co